• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ICU Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/14/25 2:49:34 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care
    Get the next $ICUI alert in real time by email
    icui-20250513
    falseICU MEDICAL INC/DE000088398400008839842025-05-132025-05-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) May 13, 2025

    ICU MEDICAL, INC.

    (Exact name of registrant as specified in its charter)
    Delaware001-3463433-0022692
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    951 Calle Amanecer,San Clemente,California92673
    (Address of principal executive offices)(Zip Code)

    (949) 366-2183
    Registrant's telephone number, including area code

    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC
    (Global Select Market)
    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On May 13, 2025, ICU Medical, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the third amendment to the Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan (the "2011 Plan" and such amendment, the "Plan Amendment"). The Plan Amendment was adopted by the Company’s Board of Directors on March 28, 2025 and became effective on such date, subject to approval by the Company’s stockholders.

    The Plan Amendment makes the following material changes to the 2011 Plan:

    (i)increases the number of shares available for issuance under the 2011 Plan by 2,150,000 shares of common stock to an aggregate of 8,515,510 shares of common stock; and

    (ii)increases the number of shares which may be granted as incentive stock options (“ISOs”) under the 2011 Plan by 2,150,000 shares of common stock to an aggregate of 8,515,510 shares of common stock;

    The material terms and conditions of the Plan Amendment are described in the section entitled “Proposal 2 – Approve an amendment to the Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 3, 2025. The foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Plan Amendment, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

    Item 5.07.  Submission of Matters to a Vote of Security Holders.
    At the Annual Meeting held on May 13, 2025, the following proposals were voted on by the Company’s stockholders, and the results were as set forth below:

    Proposal 1.  Election of directors.
            
    Name of Nominee Votes For Withheld Broker Non-Votes
    Vivek Jain  21,022,893550,2092,145,693
    David C. Greenberg21,267,942305,1602,145,693
    Elisha W. Finney21,315,470257,6322,145,693
    David F. Hoffmeister21,162,210410,8922,145,693
    Donald M. Abbey21,374,590198,5122,145,693
    Laurie Hernandez21,382,937190,1652,145,693
    Kolleen T. Kennedy21,379,544193,5582,145,693

    The Company’s stockholders elected each of the director nominees to serve as a director until the next annual meeting of stockholders or until their respective successor is duly elected and qualified.

    Proposal 2. Approve an Amendment to the Amended and Restated ICU Medical, Inc. 2011 Stock Incentive Plan.

    Votes For Votes Against Votes Abstained Broker Non-Votes
    20,766,007772,68734,4082,145,693

    The Company's stockholders approved the Plan Amendment.

    Proposal 3. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
            



    Votes For Votes Against Votes AbstainedBroker Non-Votes
    22,516,6511,165,48036,6640

    The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    Proposal 4.  Approve, on an advisory basis, the Company’s named executive officer compensation.
            
    Votes For Votes Against Votes Abstained Broker Non-Votes
    20,628,280883,29561,5272,145,693

    The Company’s stockholders approved, on an advisory basis, the Company’s named executive officer compensation.

    Proposal 5. Approve, on an advisory basis, a stockholder proposal to adopt simple majority voting.

    Votes For Votes Against Votes Abstained Broker Non-Votes
    18,429,6343,094,80548,6632,145,693

    The Company’s stockholders approved, on an advisory basis, the stockholder's proposal regarding simple majority voting.

    Item 9.01 Financial Statements and Exhibits.

    (d)    Exhibits

    10.1     Third Amendment to ICU Medical, Inc. Amended and Restated 2011 Stock Incentive Plan

    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).




    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
        ICU MEDICAL, INC.
    Date: May 14, 2025  By: /s/ Brian M. Bonnell
       Brian M. Bonnell
       Chief Financial Officer


    Get the next $ICUI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICUI

    DatePrice TargetRatingAnalyst
    3/12/2025$205.00 → $197.00Outperform → Strong Buy
    Raymond James
    12/11/2024$200.00Hold → Buy
    Jefferies
    10/14/2024$183.00Hold
    Jefferies
    6/21/2024Hold
    Needham
    6/17/2024$135.00Mkt Perform → Outperform
    Raymond James
    11/8/2022Outperform → Mkt Perform
    Raymond James
    2/28/2022$286.00 → $265.00Outperform
    Raymond James
    10/22/2021$302.00 → $280.00Overweight
    Keybanc
    More analyst ratings

    $ICUI
    SEC Filings

    See more
    • ICU Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

      5/14/25 2:49:34 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by ICU Medical Inc.

      10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)

      5/8/25 5:06:47 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

      5/8/25 4:08:03 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Financials

    Live finance-specific insights

    See more
    • ICU Medical Announces First Quarter 2025 Results

      SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

      5/8/25 4:05:00 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Announces Time of First Quarter 2025 Earnings Conference Call

      SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2025 earnings release and conference call. The Company will release its first quarter 2025 results on Thursday, May 8, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 8, 2025. The call can be accessed at (800) 225-9448, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's webs

      4/24/25 8:30:00 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance

      SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quarter 2024 revenue was $629.8 million, as compared to $587.9 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2024 was $227.3 million, as compared to $171.6 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2024 was 36.1%, as compared to 29.2% in the same period in the prior year. GAAP net loss for the fourth quarter of 2

      2/27/25 4:05:00 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ICU Medical Announces First Quarter 2025 Results

      SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

      5/8/25 4:05:00 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America

      The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. SAN CLEMENTE, Calif. and TOKUSHIMA, Japan, May 1, 2025 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), a subsidiary of Otsuka Holdings Co., Ltd. engaged in the global manufacturing and sale of IV solutions, together announce the formation of Otsuka ICU Medical LLC—a new joint venture aimed at

      5/1/25 8:30:00 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Announces Time of First Quarter 2025 Earnings Conference Call

      SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2025 earnings release and conference call. The Company will release its first quarter 2025 results on Thursday, May 8, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 8, 2025. The call can be accessed at (800) 225-9448, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's webs

      4/24/25 8:30:00 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

      SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

      11/12/24 3:44:43 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

      SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

      11/8/24 10:34:33 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ICU Medical Inc.

      SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)

      7/18/24 7:06:07 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC

      Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling

      5/17/23 4:40:03 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICU Medical upgraded by Raymond James with a new price target

      Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously

      3/12/25 7:28:15 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical upgraded by Jefferies with a new price target

      Jefferies upgraded ICU Medical from Hold to Buy and set a new price target of $200.00

      12/11/24 7:52:44 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on ICU Medical with a new price target

      Jefferies initiated coverage of ICU Medical with a rating of Hold and set a new price target of $183.00

      10/14/24 7:34:44 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Voigtlander Christian B. sold $1,523,301 worth of shares (11,111 units at $137.10) and exercised 11,111 shares at a strike of $96.83 (SEC Form 4)

      4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

      5/15/25 4:57:09 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Chief Information Officer Sousa Ben sold $274,714 worth of shares (2,000 units at $137.36), decreasing direct ownership by 81% to 479 units (SEC Form 4)

      4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

      5/15/25 4:55:39 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Director Finney Elisha W converted options into 1,723 shares, increasing direct ownership by 81% to 3,852 units (SEC Form 4)

      4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

      5/14/25 11:02:16 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Leadership Updates

    Live Leadership Updates

    See more
    • Carlyle Group and WP Carey Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

      NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt

      11/27/23 6:28:00 PM ET
      $AVTA
      $BANC
      $CG
      $CWEN
      Finance: Consumer Services
      Finance
      Major Banks
      Investment Managers